A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. - Wikidata - awgldk - TriplyDB

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

http://www.wikidata.org/entity/Q35081168

about

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review.Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study.Live virus vaccines in transplantation: friend or foe?The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.The herpes zoster subunit vaccine.Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Herpes zoster and the search for an effective vaccine.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.Herpes zoster after autologous hematopoietic stem cell transplantation.Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.Vaccine profile of herpes zoster (HZ/su) subunit vaccine.A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.Adjuvant system AS01: helping to overcome the challenges of modern vaccines.Varicella Zoster Virus and Giant Cell Arteritis.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Vaccines for the elderly: current use and future challenges.Herpes Zoster in the Older Adult.Studies with herpes zoster vaccines in immune compromised patients.Varicella and herpes zoster vaccine development: lessons learned.Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.[Protection from a dormant time bomb: The development of effective vaccines against herpes zoster].Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Recent advances in understanding and managing infectious diseases in solid organ transplant recipients.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity

P2860

Q33724403-65A81B42-C719-4123-9E4B-048ADCBCC5F5 Q34446365-94C03A52-E556-44CF-BD71-DAEE55F6BA16 Q37320197-A7B15CAE-6A1C-4A4C-8B66-36436AED5477 Q37605555-AC1809C8-ECF9-4ED9-8075-45647AEF997C Q38419551-8DB4D2F6-B5E8-46C5-8BF4-F611FECDF1FB Q38682515-65003FAF-95D9-4680-9A61-69425FB9B4AD Q38728931-C247B628-7849-4157-B573-8E2B8ECD0959 Q38804622-6A6212D4-BC26-439D-9042-7D0A559D7512 Q38831062-CBA16A5C-22CF-4491-928C-9819BF5EF828 Q38837769-0A1ECE9B-0F66-4A6E-83DB-10398DC99D6F Q39063520-9054165F-A813-442B-9141-194BD05A9BB0 Q39173692-1DDB99CC-C753-4E2E-A0E8-42F73F831E5A Q40107328-91EE64C0-A315-46B9-8299-B8D17EAD3FA4 Q40208840-66F1ECB3-7436-4944-B1AD-B2151925C13B Q40234780-F45E91E2-08D0-4207-A7CE-59D09051661B Q42051427-12D547D8-5720-4BAF-A5CB-F02AE739BA46 Q42765034-8B975F91-5DA0-4260-8EF2-9D2EB34BEE91 Q46892547-604B7045-77E1-47E4-8249-5B3E5752139D Q47547388-66DC45FF-C037-4EB0-B793-B24BCD22CF64 Q47597541-A4291665-1F95-4C9F-BCA6-6E2095F8D279 Q47605669-A726B1A2-18A7-46E6-9093-0BEC980C7406 Q47607699-6B699A6D-C1AF-43FA-9682-62F59BD033E4 Q48505883-C2EB39F5-E849-426D-AC65-63F0715CF75F Q50619438-12553EF1-E13A-43CB-BBFF-4AFAD2D9D47D Q52801394-B3BE8372-0CB5-4A1A-A2F0-388A24C67C1B Q55084357-CB3084E0-363E-4CFA-B677-534E76F722B7 Q56888201-E0DA417B-7E68-48CF-94F8-1F10F12A6084 Q58584452-5EF69274-F544-4F8F-8719-98D11DBF0341

P2860

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

http://www.wikidata.org/entity/Q35081168

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@ast

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@en

type

label

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@ast

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@en

prefLabel

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@ast

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@en

P1433

Q35081168-CAD60373-7543-4F9E-B663-8E9AA662B356

P1476

Q35081168-5A924B0D-5934-45A3-A704-6D39F3B2402C

P2093

Q35081168-34D907C6-1FA4-4374-A203-73757D860D64

Q35081168-43A045D0-05EB-4248-B246-65A6A091A028

Q35081168-51CA5313-A238-4CF0-9919-EF1C5D45DC65

Q35081168-5E3FE5AE-1A17-4863-8DDC-BEC3024CDAE7

Q35081168-861BBDD8-FA3C-4400-8444-02F0890DF12A

Q35081168-88C815BF-5A22-429C-BB7C-ED455461F3C5

Q35081168-9D6B3DA4-3145-4B4C-BACE-5E6587C7EB6D

Q35081168-FC1F0CE9-1A2D-40CC-8F73-748BAFD8100B

P2860

Q35081168-00BF4F2E-2062-4D2F-BE48-5F3D15F40F32

Q35081168-323BDF7D-BF47-4D9B-B036-683EB89B9EFD

Q35081168-33EEF36A-4B0A-4B8A-A17D-3080307E6DC5

Q35081168-37008CD7-E020-411B-961B-42CE8E1B3F8B

Q35081168-3B1C39C1-5D4F-453D-BB02-B356746E6D55

Q35081168-43BAE904-9BC6-4217-9C1D-DBCDB1EA84BC

Q35081168-44D8AA2D-F0A6-4994-B425-70A4E45C5F1B

Q35081168-4ED8DF80-855B-4C09-993E-3C5C5C38A217

Q35081168-5F86F3C3-7602-4305-8BF2-F77AED9F4354

Q35081168-64583AFD-C1F0-46E9-AF25-C92DCE083D1E

P304

Q35081168-1473434B-D387-4818-92DC-565AE632B1BE

P31

Q35081168-149AC95B-C19F-4E90-869A-B07E44B9379B

P356

Q35081168-6E73CEBA-08C7-4CDB-B1CC-993DDA9FD017

P407

Q35081168-5E49D0E9-0C32-4254-81F3-0A4BA88A972D

P433

Q35081168-3DD502B7-F247-4ACB-859D-88558F05C04D

P478

Q35081168-7810018E-EC34-4264-A5D9-A9780F686889

P50

Q35081168-73F0A0F2-ADFA-4F69-AC20-55EA0632729E

Q35081168-994C4BBD-D0E4-4516-A40F-85228F74BA09

Q35081168-9CC2D139-D0DD-4194-B731-6CD209870DF5

Q35081168-AABE227C-819B-4BBD-87B0-3A949AA49A9F

Q35081168-B806FAD4-DE5F-4F42-86DA-7A9B9F11878A

P577

Q35081168-AFDFFC71-3F34-4654-B1B0-94FDF9F69AD6

P5875

Q35081168-92F0F24E-A642-49AB-868B-9D7566E45015

P698

Q35081168-2511B4AE-A2DD-4AB4-BD40-9F4B6EC4A3A5

P932

Q35081168-84DD22D1-797E-44F6-9135-B754B34AC626

P356

BLOOD-2014-04-573048

P1433

P1476

A phase 1/2 study of an adjuva ...... ic cell transplant recipients.

@en

P2093

Charalambos Andreadis

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

Mohamed El Idrissi

http://www.w3.org/2001/XMLSchema#string

Sanjeet S Dadwal

http://www.w3.org/2001/XMLSchema#string

Sherif B Mossad

http://www.w3.org/2001/XMLSchema#string

Thomas C Heineman

http://www.w3.org/2001/XMLSchema#string

Thomas C Shea

http://www.w3.org/2001/XMLSchema#string

P2860

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection

Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients.

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.

A review of the varicella vaccine in immunocompromised individuals.

P304

2921-2929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-04-573048

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Jo-Anne H. Young

Francisco M. Marty

Genovefa Anna Papanicolaou

Elchonon M Berkowitz

Keith M. Sullivan

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265863647

http://www.w3.org/2001/XMLSchema#string

P698

25237196

http://www.w3.org/2001/XMLSchema#string

P932

4327150

http://www.w3.org/2001/XMLSchema#string